Aclaris Therapeutics Inc (ACRS)
R&D Expense Growth
56.75%
Fiscal year · Period ending:
ACRS R&D Expense Growth
Latest reported56.75%period ending
Latest reported56.75%period ending
ACRS FY R&D Growth (YoY) (0.00% → 56.75%)
Latest values, visible window
High-resolution chart · PNG
ACRS r&d expense growth history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 56.7469% | |
| -65.8623% | |
| 26.4365% | |
| 77.6025% | |
| 49.3387% | |
| -54.7944% | |
| 2.9996% | |
| 58.3539% | |
| 18.8613% | |
| 118.2411% | |
| 135.7308% | |
| 86.5539% | |
| 0% |